| Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group T André, D Vernerey, SA Im, G Bodoky, R Buzzoni, S Reingold, F Rivera, ... Annals of Oncology 31 (2), 246-256, 2020 | 33 | 2020 |
| Association of bevacizumab plus oxaliplatin-based chemotherapy with disease-free survival and overall survival in patients with stage II colon cancer: a secondary analysis of … B Chibaudel, J Henriques, M Rakez, B Brenner, TW Kim, ... JAMA network open 3 (10), e2020425-e2020425, 2020 | 16 | 2020 |
| Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. AD Wagner, M Rakez, B Chibaudel, R Adams, JR Zalcberg, LB Saltz, ... Journal of Clinical Oncology 38 (15_suppl), 4029-4029, 2020 | 13 | 2020 |
| Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: findings from the ACCENT database of 4934 patients O Margalit, B Boursi, M Rakez, A Thierry, G Yothers, N Wolmark, ... Clinical colorectal cancer 20 (2), 130-136, 2021 | 7 | 2021 |
| Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in … JB Bachet, B Chibaudel, M Rakez, RM Goldberg, NC Tebbutt, ... Journal of Clinical Oncology 39 (15_suppl), 3575-3575, 2021 | 2 | 2021 |
| Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of … B Chibaudel, J Henriques, M Rakez JAMA NETWORK OPEN 4 (2), 2021 | 1 | 2021 |
| Longitudinal changes in deep learning-estimated breast density and their impact on the risk of screen-detected breast cancer: The DeepJoint Algorithm M Rakez, J Guillaumin, A Chick, G Coureau, F Chamming's, P Fillard, ... arXiv preprint arXiv:2403.13488, 2024 | | 2024 |
| Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD … BA Weinberg, M Rakez, B Chibaudel, T Maughan, R Adams, JR Zalcberg, ... Journal of Clinical Oncology 39 (3_suppl), 108-108, 2021 | | 2021 |
| Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials. O Margalit, B Boursi, M Rakez, T André, G Yothers, N Wolmark, ... Journal of Clinical Oncology 38 (4_suppl), 118-118, 2020 | | 2020 |
| Model-based approach for group sequential and adaptive designs in parallel and cross-over bioequivalence studies M Rakez, J Bertrand, F Loingeville, TT Nguyen, F Mentré, A Babiskin, ... | | |
